https://biotechmorning.com/news/lilly-jaypirca-cll-frontline-surprise Biotech Morning en 2026-06-15T14:28:16.646Z Lilly's Cancer Drug Just Aced a Test Nobody Expected It to Pass https://biotechmorning.com/news/merck-terns-pharmaceuticals-acquisition-6-7-billion Biotech Morning en 2026-06-15T14:27:24.299Z Merck Just Paid $6.7 Billion for a Company That Was Worth $300 Million Two Years Ago https://biotechmorning.com/news/allogene-off-the-shelf-car-t-breaks-wall-street Biotech Morning en 2026-06-15T14:26:30.116Z The $4,000 Cancer Therapy That Just Broke Wall Street https://biotechmorning.com/news/pfizer-mrna-flu-vaccine-beats-standard-shot Biotech Morning en 2026-06-15T14:25:31.567Z Pfizer's Flu Shot Just Beat the Flu Shot https://biotechmorning.com/news/legend-biotech-in-vivo-car-t-proof-of-concept Biotech Morning en 2026-06-15T14:24:43.136Z What If Your Body Could Build Its Own Cancer-Killing Cells? https://biotechmorning.com/news/asundexian-fxia-stroke-prevention-phase-3 Biotech Morning en 2026-06-15T14:23:43.269Z The Blood Thinner That Forgot How to Cause Bleeding https://biotechmorning.com/news/revolution-medicines-pancreatic-cancer-survival-breakthrough Biotech Morning en 2026-06-15T14:22:51.410Z The Pill That's Rewriting Pancreatic Cancer's Brutal Math https://biotechmorning.com/news/biogen-apellis-acquisition-ophthalmology Biotech Morning en 2026-06-15T14:22:03.328Z Biogen Just Dropped $5.6 Billion on an Eye Drug Company. Here's Why. https://biotechmorning.com/news/gilead-arcellx-7-8-billion-car-t-acquisition Biotech Morning en 2026-06-15T14:21:07.382Z Gilead Just Spent $7.8 Billion on a Tiny Protein That Could Reshape Cancer Treatment https://biotechmorning.com/news/sun-pharma-organon-acquisition-indian-pharma Biotech Morning en 2026-06-15T14:20:11.317Z The $11.75 Billion Bet That Rewrites Indian Pharma's Playbook https://biotechmorning.com/news/jj-posdinemab-alzheimer-tau-failure Biotech Morning en 2026-06-15T14:19:12.168Z The $5 Billion Alzheimer's Bet That Just Went to Zero https://biotechmorning.com/news/illumina-shrinking-again-sequencing-industry-pressure Biotech Morning en 2026-06-14T14:22:32.317Z Illumina Is Shrinking Again. The Reason Why Should Worry Every Sequencing Company. https://biotechmorning.com/news/jj-myeloma-talvey-darzalex-combo-eha-2026 Biotech Morning en 2026-06-14T14:21:37.777Z J&J Wants to Own Every Line of Myeloma Treatment. It Might Be Working. https://biotechmorning.com/news/survodutide-visceral-liver-fat-obesity-drug Biotech Morning en 2026-06-14T14:20:42.160Z The Obesity Drug That Doesn't Care About Your Scale https://biotechmorning.com/news/obesity-drug-makes-surgery-look-like-warmup Biotech Morning en 2026-06-14T14:19:51.090Z The Obesity Drug That Makes Surgery Look Like a Warm-Up https://biotechmorning.com/news/biotech-biggest-ipo-week-2026 Biotech Morning en 2026-06-14T14:18:53.973Z Biotech's IPO Market Roars Back to Life https://biotechmorning.com/news/novartis-avidity-rna-muscular-dystrophy-data Biotech Morning en 2026-06-14T14:17:51.952Z Novartis Just Dropped $12B on an RNA Bet. The First Report Card Is In. https://biotechmorning.com/news/lilly-ajax-jak2-inhibitor-early-data Biotech Morning en 2026-06-14T14:16:59.485Z Lilly Spent $2.3B on a Drug Nobody Had Tested in Humans. It Might Already Be Working. https://biotechmorning.com/news/prostate-cancer-pten-her2-moment-truqap Biotech Morning en 2026-06-14T14:16:09.991Z Prostate Cancer Just Got Its HER2 Moment https://biotechmorning.com/news/incyte-genesis-ai-drug-discovery-expansion Biotech Morning en 2026-06-14T14:15:16.491Z Incyte Just Bet $120M That an AI Can Out-Design Its Own Chemists